Sartorius


Q3 2025 preview: Sartorius poised for a recovery?

08/10/25 -"Sartorius is scheduled to report its Q3 2025 earnings on the 16th of October. Interestingly, the stock has surged c. 14% from 30 September to 7 October, in line with other key bioprocessing names, on ..."

Pages
65
Language
English
Published on
08/10/25
You may also be interested by these reports :
10/10/25
Key conclusions: Chinese manufacturers can produce Meta Rayban-like glasses for €25. The margin dilution impact of Meta Ray-Ban is probably lower ...

10/10/25
We have removed the long term margin dilution from Meta Ray-Ban in our model as we think the dilution won’t be as significant as we had previously ...

08/10/25
Sartorius is scheduled to report its Q3 2025 earnings on the 16th of October. Interestingly, the stock has surged c. 14% from 30 September to 7 ...

02/10/25
Ostensibly, it’s difficult to make an investment case for a firm, which has eroded >30% of shareholders’ wealth over five years. For Fresenius ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO